Why is it so easy to remember the lyrics to an old song—but so hard to recall something you just heard or read seconds ago? A University of Houston professor examines how the brain briefly stabilizes new information and why switching tasks too quickly can make it vanish.  

Digital Science announces the launch of Compass by Dimensions, a dedicated publication impact tracking solution designed for medical affairs teams.

In its CeraMMAM project, a team of researchers at the Karlsruhe Institute of Technology (KIT) has developed a system with which high-performance components can be produced from multiple materials in a single process using a universal binder system. This technology offers new prospects for industrial applications, particularly in medicine, mechanical engineering, and aerospace. During the Hannover Messe, April 20–24, 2026, the researchers will be presenting potential applications of multi-material additive manufacturing along with the first industrial prototypes and demonstrators at the KIT booth (Hall 11, Booth B06). 

Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced advancements to its unified AI framework for drug target discovery, integrating its previously introduced Target Identification Pro (TargetPro) and Target Identification Benchmark (TargetBench 1.0) into a validated system designed to improve the accuracy, reliability, and scalability of early-stage drug development.

Researchers at the University of Nebraska Medical Center (UNMC) published a landmark study in the scientific journal, Molecular Psychiatry. The study found a significantly increased risk of autism spectrum disorder (ASD) in children when their mothers were prescribed at least one of a group of commonly used medications during pregnancy.

The researchers looked at 6.14 million health records from mothers and their children across the United States. These studies included about one out of every three births between 2014 and 2023.

They found certain medications known to inhibit the cholesterol production pathway when taken during pregnancy were consistently associated with higher rates of ASD in children.

A new method developed with the participation of ICTER researchers shows that, in retinal imaging, less can mean more - fewer settings, fewer complications, and more information.

The more precisely we want to examine the human retina, the more clearly one of the fundamental limits of physics becomes apparent. In cellular-resolution eye imaging, the same trade-off has applied for years - tiny structures can be seen with impressive sharpness, but only within a very thin layer of tissue. To view the entire retina, researchers usually have to refocus and acquire several separate scans in a repetitive manner. An international team led by Dawid Borycki and Maciej Wojtkowski from ICTER, together with Zhuolin Liu and Daniel X. Hammer from the FDA Center for Devices and Radiological Health (CDRH), has now shown that this limitation can be overcome.

Rather than making the hardware even more complex, the researchers combined optical and computational procedures. This is an important step not only for advancing imaging physics, but also for improving the diagnosis of eye diseases and neurological disorders. The details are described in the article, “Computational aberration correction enables full-thickness retinal imaging with adaptive optics optical coherence tomography,” published in Biocybernetics and Biomedical Engineering.

Chemokines, acting as "traffic controllers" in the tumor microenvironment, regulate immune cell infiltration and local immunity. This review summarizes the chemokine expression profiles in tumors, their diverse roles in pro- and anti-tumor immunity, current targeting strategies (inhibition, delivery, engineering), and synergistic potential ability with other immunotherapies. Despite challenges, targeting the chemokine receptor axis holds great promise for reprogramming the tumor microenvironment and advancing precision cancer therapy.

A research team at IDM is leading the development of a sensor that paves the way for the rapid, selective and cost-effective detection of active tuberculosis. The device detects the presence of a protein secreted by Mycobacterium tuberculosis, the bacterium that causes the disease. It provides results in just 60 minutes – significantly less time than conventional methods, such as microbiological culture, which can take several weeks.